Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Moodys
Chinese Patent Office
McKesson
Johnson and Johnson

Generated: July 16, 2019

DrugPatentWatch Database Preview

Patent: 5,580,755

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,580,755
Title: Human pluripotent granulocyte colony-stimulating factor
Abstract:Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (\"hpG-CSF\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s): Souza; Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:08/459,298
Patent Claims:see list of patent claims

Details for Patent 5,580,755

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31 ➤ Try a Free Trial Amgen Inc. (Thousand Oaks, CA) ➤ Try a Free Trial RX Orphan company
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20 ➤ Try a Free Trial Amgen Inc. (Thousand Oaks, CA) ➤ Try a Free Trial RX company
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20 ➤ Try a Free Trial Amgen Inc. (Thousand Oaks, CA) ➤ Try a Free Trial RX company
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20 ➤ Try a Free Trial Amgen Inc. (Thousand Oaks, CA) ➤ Try a Free Trial RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20 ➤ Try a Free Trial Amgen Inc. (Thousand Oaks, CA) ➤ Try a Free Trial RX company
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 5,580,755

Country Patent Number Publication Date
South Africa 8606412 Apr 29, 1987
World Intellectual Property Organization (WIPO) 8701132 Feb 26, 1987
United States of America 2003086936 May 08, 2003
United States of America 4810643 Mar 07, 1989
United States of America 4999291 Mar 12, 1991
United States of America 5582823 Dec 10, 1996
United States of America 5676941 Oct 14, 1997
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Julphar
Chubb
UBS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.